<DOC>
	<DOCNO>NCT02305277</DOCNO>
	<brief_summary>Single-centre , open-label , randomised , three-part , two-way crossover study 84 healthy volunteer . In part , study consist two consecutive single-dose treatment period separate washout period least 14 day .</brief_summary>
	<brief_title>Relative Bioavailability Bioequivalence Of Different Formulations Opicapone Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Opicapone</mesh_term>
	<criteria>A sign date informed consent form studyspecific screen procedure perform ; Male female subject age 18 45 year , inclusive ; Body mass index ( BMI ) 18 30 kg/m2 inclusive ; Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead electrocardiogram ( ECG ) ; Negative test hepatitis B surface antigen ( HBsAg ) , anti hepatitis C virus antibody ( HCV Ab ) antihuman immunodeficiency virus antibody ( HIV1 HIV2 Ab ) screening ; Clinical laboratory test result clinically acceptable screen admission treatment period ; Negative screen alcohol drug abuse screen admission treatment period ; Nonsmokers exsmokers least 3 month ; Able participate , willing give write informed consent comply study restriction . If female : She childbearing potential reason surgery , childbearing potential , used effective nonhormonal method contraception [ intrauterine device intrauterine system ; condom occlusive cap ( diaphragm cervical vault cap ) spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ] duration study ; She negative serum pregnancy test screen negative urine pregnancy test admission treatment period . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder , clinically relevant surgical history ; Had clinically relevant finding laboratory test , particularly abnormality coagulation test , abnormality liver function test ; Had history relevant atopy drug hypersensitivity ; Had history alcoholism and/or drug abuse ; Consumed 14 unit alcohol per week [ 1 unit alcohol = 280 mL beer ( 34° ) = 100 mL wine ( 1012° ) = 30 mL spirit ( 40° ) ] ; Had significant infection know inflammatory process screen admission treatment period ; Had acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period ; Had use medicine within 2 week admission first period could affect safety study assessment , Investigator 's opinion ; Had previously receive opicapone ; Had use investigational drug participate clinical trial within 90 day prior screen ; Had participate 2 clinical trial within 12 month prior screen ; Had donate receive blood blood product within 3 month prior screen ; Were vegetarian , vegan medical dietary restriction ; Could communicate reliably Investigator ; Were unlikely cooperate requirement study ; Were unwilling unable give write informed consent ; If female : She pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>